USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Agouron Pharmaceuticals Inc.
Address:
505 Coast Blvd
La Jolla, CA 92037
Phone:
N/A
URL:
N/A
EIN:
N/A
DUNS:
N/A
Number of Employees:
28
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $300,000.00 6
SBIR Phase II $900,000.00 2

Award List:

IMMUNOLOGICAL AND DNA HYBRIDIZATION ASSAYS WHICH EMPLOY SPECIFIC ANTIBODY AND DNA PROBES ARE PROVING TO BE VERY VALUABLE IN THE IDENTIFICATION OF PATHOGENS AND IN THE DIAGNOSIS OF GENETIC DISEASES.

Award Year / Program / Phase:
1985 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Richard c. ogden , PRINCIPAL INVESTIGATOR
Abstract:
Immunological and dna hybridization assays which employ specific antibody and dna probes are proving to be very valuable in the identification of pathogens and in the diagnosis of genetic diseases. the objective of this project is to improve the sensitivity, safety, and convenience of diagnostic… More

DEVELOPMENT OF DIAGNOSTIC PROBES FOR AUTOIMMUNE DISEASE

Award Year / Program / Phase:
1985 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Sallie O. Hoch , Principal Investigator
Abstract:
N/a

MAJOR OBJECTIVES OF THIS RESEARCH ARE TO (1) ISOLATE 100 MG OF HOMOGENEOUS DIHYDROFOLATE REDUCTASE (DHFR) FROM CANDIDA ALBICANS, (2) CRYSTALLIZE THE ENZYME, AND (3) DETERMINE ITS THREE-DIMENSIONAL STRUCTURE USING X-RAY DIFFRACTION METHODS.

Award Year / Program / Phase:
1986 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
David a matthews , PRINCIPAL INVESTIGATOR
Abstract:
Major objectives of this research are to (1) isolate 100 mg of homogeneous dihydrofolate reductase (dhfr) from candida albicans, (2) crystallize the enzyme, and (3) determine its three-dimensional structure using x-ray diffraction methods.armed with the resulting detailed knowledge of the… More

MAJOR OBJECTIVES OF THIS RESEARCH ARE TO (1) ISOLATE 100 MG OF HOMOGENEOUS DIHYDROFOLATE REDUCTASE (DHFR) FROM PSEUDOMONAS AERUGINOSA, (2) CRYSTALLIZE THE ENZYME, AND (3) DETERMINE ITS THREE-DIMENSIONAL STRUCTURE USING X-RAY DIFFRACTION METHODS.

Award Year / Program / Phase:
1986 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
David a matthews , PRINCIPAL INVESTIGATOR
Abstract:
Major objectives of this research are to (1) isolate 100 mg of homogeneous dihydrofolate reductase (dhfr) from pseudomonas aeruginosa, (2) crystallize the enzyme, and (3) determine its three-dimensional structure using x-ray diffraction methods. armed with the resulting detailed knowledge of the… More

RETARDATION

Award Year / Program / Phase:
1986 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Cila blatt , PRINCIPAL INVESTIGATOR
Abstract:
This project describes the isolation of dna probes linked tothe site in the human x chromosome involved in fragility of the chromosome under some growth conditions ("fragile x site") and known to be associated with a high incidence of mental retardation. such sequences may be useful in under-… More

DEVELOPMENT OF DIAGNOSTIC PROBES FOR AUTOIMMUNE DISEASE

Award Year / Program / Phase:
1988 / SBIR / Phase II
Award Amount:
$400,000.00
Agency:
HHS
Principal Investigator:
Sallie O. Hoch , Principal Investigator
Abstract:
A characteristic feature of many rheumatic diseases is the presence of circulating antinuclear antibodies. assays based on the measurement of these antibodies are established in the clinical laboratory for the diagnosis of these diseases, but often without the benefit of having well-characterized or… More

SITE-DIRECTED DRUG DESIGN AGAINST PLASMODIUM FALCIPARUM.

Award Year / Program / Phase:
1988 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

SITE-DIRECTED DRUG DESIGN AGAINST PLASMODIUM FALCIPARUM.

Award Year / Program / Phase:
1989 / SBIR / Phase II
Award Amount:
$500,000.00
Agency:
HHS
Principal Investigator:
Abstract:
The ultimate objective of this project is to utilize the information available in the three-dimensional crystal structure of an enzyme in the rational design of drugs whichwill be effective against plasmodium falciparum. the specific enzyme target is the bifunctional dihydrofolate… More